Heron Therapeutics | HRTX - Operating Profit


Heron Therapeutics reported $38K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 39.84M 1.13M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Emergent BioSolutions USD -218M 69.9M Jun/2023
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 9.96M 5.33M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026